CEO Shalabh Gupta was paid $2,391,621 in fiscal year 2025, ↓ down 2.0% from fiscal year 2024 (SEC filing 0001213900-26-049690 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,391,621 ↓ Shalabh Gupta total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
You have just read Unicycive Therapeutics's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper UNCY reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
UNCY's next annual pay disclosure, estimated April 30, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Shalabh Gupta | $572,000 | $486,200 | $0 | $1,333,421 | $0 | $0 | — | $2,391,621 |
| Chief Executive Officer | ||||||||
| Doug Jermasek | 363,000 | 77,138 | 0 | 41,028 | 0 | 0 | — | 481,166 |
| Executive VP, Corporate Strategy | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Shalabh Gupta | $2,391,621 | $2,439,884 | — | ↓ −48,263 |
| Doug Jermasek | 481,166 | 873,346 | — | ↓ −392,180 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Gaurav Aggarwal, M.D | Former director (through FY2025) | $149,486 |
| Saraswati Kenkare-Mitra, Ph.D | Independent Director | $147,486 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Shalabh Gupta | Option | 1,971 | 7.5 | — |
| Shalabh Gupta | Option | 146,400 | 7.5 | — |
| Shalabh Gupta | Option | 76,977 | 11.4 | — |
| Shalabh Gupta | Option | 15,526 | 3.4 | — |
| Shalabh Gupta | Option | 325,000 | 4.71 | — |
| Shalabh Gupta | Option | 642 | 7.5 | — |
| Shalabh Gupta | Option | 42,344 | 7.5 | — |
| Shalabh Gupta | Option | 27,024 | 11.4 | — |
| Shalabh Gupta | Option | 5,450 | 3.4 | — |
| Shalabh Gupta | Option | 90,000 | 4.71 | — |
| Doug Jermasek | Option | 1,261 | 7.5 | — |
| Doug Jermasek | Option | 42,344 | 7.5 | — |
| Doug Jermasek | Option | 27,024 | 11.4 | — |
| Doug Jermasek | Option | 5,450 | 3.4 | — |
| Doug Jermasek | Option | 10,000 | 4.71 | — |
The Compensation Committee recommends to the Board for approval the overall compensation philosophy for the company and periodically reviews it to ensure it is appropriate and does not incentivize unnecessary and excessive risk taking. Executive compensation consists of base salary, annual discretionary bonuses based on performance objectives, and equity-based compensation awards.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Gaurav Aggarwal, M.DIndependent · Audit · Compensation (Chair) · Nominating and Governance · Departed during FY | $65,000 | $0 | $84,486 | — | — | $149,486 |
| Saraswati Kenkare-Mitra, Ph.DIndependent · Audit · Compensation · Nominating and Governance (Chair) | 63,000 | 0 | 84,486 | — | — | 147,486 |
| Shalabh Gupta, M.DEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $50,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $128,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $128,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Unicycive Therapeutics | 2025 | Shalabh Gupta | $572,000 | $0 | $1,333,421 | $0 | $2,391,621 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Shalabh Gupta | DEF 14A | 2026-04-30 | 0001213900-26-049690 | Section “Executive Compensation”. As printed: 2,391,621. Filing ↗machine: r1 · c23 · span 136280–136289 |
| 2 | Section 01, Doug Jermasek | DEF 14A | 2026-04-30 | 0001213900-26-049690 | Section “Executive Compensation”. As printed: 481,166. Filing ↗machine: r7 · c23 · span 142267–142274 |
| 3 | Section 08, Gaurav Aggarwal, M.D | DEF 14A | 2026-04-30 | 0001213900-26-049690 | Section “Director Compensation”. As printed: 149,486. Filing ↗machine: span 242326–242333 |
| 4 | Section 08, Saraswati Kenkare-Mitra, Ph.D | DEF 14A | 2026-04-30 | 0001213900-26-049690 | Section “Director Compensation”. As printed: 147,486. Filing ↗machine: span 243696–243703 |
| 5 | Section 08, Shalabh Gupta, M.D | DEF 14A | 2026-04-30 | 0001213900-26-049690 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 6 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 7 | Section 09b board cost (computed) | Computed | — | — | Cash 128,000 + equity 0 + all other 0 = 128,000, summed across the director compensation table rows.machine: formula: Σ = 128,000 |
| 8 | Unicycive Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001213900-26-049690 | CEO total compensation as printed in Unicycive Therapeutics's own proxy. As printed: 2,391,621. Filing ↗machine: r1 · c23 · span 136280–136289 |